Ultragenyx Pharmaceutical Inc expected to post a loss of $1.30 a share - Earnings Preview

Ultragenyx Pharmaceutical

01/08/2025 23:56

Ultragenyx Pharmaceutical Inc RARE.OQ RARE.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2025

The Novato California-based  company is expected to report a 9.9% increase in revenue to $161.591 million from $147.03 million a year ago, according to the mean estimate from 16 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Ultragenyx Pharmaceutical Inc is for a loss of $1.30 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $82.00, about 65.3% above its last closing price of $28.44

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.59
-1.61
-1.57
Beat
2.7
Dec. 31 2025
-1.20
-1.29
-1.39
Missed
-7.7
Sep. 30 2024
-1.50
-1.45
-1.40
Beat
3.5​
Jun. 30 2024
-1.66
-1.69
-1.52
Beat
10.3
​​Mar. 31 2024
-1.76
-1.73
-2.03
Missed
-17.2
Dec. 31 2023
-1.66
-1.62
-1.52
Beat
6.1​
Sep. 30 2023
-2.28
-2.08
-2.23
Missed
-7.3
Jun. 30 2023
-2.08
-2.07
-2.25
Missed
-8.5

This summary was machine generated August 1 at 22:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)